SAVE MONEY ON TRAVEL DEALS

The newly investigated compound, known as cDPCP, is an analogue of cisplatin, a potent anticancer agent. The study found cDPCP might better target colorectal cells, potentially sparing other body tissues from damage, said Massachusetts Institute of Technology researchers.

"This compound, the antitumor properties of which were established in mice over 20 years ago, emerged in our search for platinum anticancer drug candidates with cellular uptake properties analogous or superior to those of oxaliplatin", said Professor Stephen Lippard.

He said cDPCP could become an alternative to oxaliplatin, which was approved by the FDA in 2004 and is usually the first therapeutic line of defense against colorectal cancer -- the fifth most common cancer in the United States.

The study that include MIT graduate students Ryan Todd, Michael McCormick and Katherine Lovejoy; Shuzhong Zhang and Kathleen Giacomini of the University of California-San Francisco; J. Alejandro D'Aquino of Brandeis University; and Joyce Reardon and Aziz Sancar of the University of North Carolina appeared in the online edition of the Proceedings of the National Academy of Sciences.

 BREAKING STORIES

Boston Herald Tony Massarotti Column: Nation Prays for Carl Yastrzemski

Mayor targeted for recall after scandal

Wheelchair lift stolen in mid-day

Massachusetts governor among DNC speakers

MicroRNA activation mystery is solved

John, Elizabeth Edwards speech still on

Verizon, IBEW negotiate Mass. contract

UBS settles Mass. probe for $4.4 million

Report: Company hired connected lawyer

Kerry demands Web site make correction

Obesity linked to brain's reward system

Soft, juice drinks daily ups diabetes risk

Study: Cell more controlling than thought

Chesney joins Farm Aid lineup

Man against Census skipping same-sex pairs

Kennedy finishes tumor treatment phase

Foreclosure led to suicide, police say

Natalie Cole plays Point Breeze party

Canada's TD Bank drops U.S. name battle

Mass. officials say West Nile seen earlier